Serum phosphate increase during short-term beta-adrenoceptor blockade in thyrotoxicosis

Area of Science:

• Endocrinology
• Pharmacology
• Clinical Chemistry

Background:

• Hyperthyroidism is associated with various metabolic disturbances.
• Beta-adrenergic-blocking agents are commonly used to manage hyperthyroid symptoms.

Purpose of the Study:

• To investigate the effects of acute and short-term treatment with different beta-blockers on serum electrolytes in hyperthyroid patients.
• To explore the potential mechanism behind observed electrolyte changes, specifically hyperphosphatemia.

Main Methods:

• Thirty-one patients with hyperthyroidism were treated with four different beta-adrenergic-blocking agents (acebutolol, oxprenolol, pindolol, timolol).
• Blood plasma electrolyte levels (phosphate, albumin, creatinine, sodium, potassium, calcium) were monitored during acute and short-term treatment.
• Statistical analysis was performed to determine significant changes (p < 0.05).

Main Results:

• Serum phosphate levels increased significantly within four hours and remained elevated after one week of treatment with all tested beta-blockers.
• Albumin levels decreased after four hours but returned to baseline after one week.
• Serum creatinine increased after one week in the acebutolol group; sodium, potassium, and albumin-corrected calcium showed no significant changes.
• The hyperphosphatemic effect was observed with both cardioselective (acebutolol) and non-cardioselective beta-blockers.

Conclusions:

• Beta-adrenergic blockade, particularly involving beta 1-adrenoceptors, leads to a consistent increase in serum phosphate in hyperthyroid patients.
• The observed hyperphosphatemia is a notable side effect of beta-blocker therapy in this population.
• Further research may be warranted to fully elucidate the clinical implications of beta-blocker-induced hyperphosphatemia in hyperthyroidism.